Dr. Emily Frydendall, MD

Dr. Frydendall practices at UCHealth Poudre Valley Hospital in Fort Collins, Colorado, part of UCHealth.

Dr. Frydendall's NPI, 1457765117, was assigned on June 19, 2014. Dr. Frydendall graduated from University of Colorado School of Medicine, Denver in 2014. Dr. Frydendall holds Colorado license 57817.

Dr. Frydendall's primary practice is UCHealth Poudre Valley Hospital, at 1024 S Lemay Ave, Fort Collins, CO 80524 in Larimer County. The practice phone is (970) 495-7000.

Dr. Frydendall's primary practice is UCHealth Poudre Valley Hospital in Fort Collins, Colorado, part of UCHealth. Dr. Frydendall is also affiliated with UCHealth Medical Center of the Rockies. The medical group on file is Northern Colorado Hospitalists. Dmand AI also links Dr. Frydendall to 2 more hospitals, 2 group practices and clinics, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Frydendall practices, 7 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Frydendall's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dr. Frydendall is licensed in Colorado.

CMS data shows 631 Medicare services from Dr. Frydendall across 6 procedure codes in 2024, for 247 Medicare patients. Medicare paid $54,117 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 247 Medicare patients who saw Dr. Frydendall in 2024. The largest group is 75 to 84, with 104 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Frydendall's median patient age at 78, with 52% women.

In 2024, Dr. Frydendall wrote 230 Medicare Part D claims for 105 patients. 90% of them were for generic drugs. CMS names the drug for 18 of them, across 1 drug with 11 or more claims each, at $97 in total drug cost. In 2023, CMS named 41 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Frydendall for performance year 2024, reported as part of a group. Dr. Frydendall accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Frydendall in 2010. The most frequent topics are Recovery of Function. Dr. Frydendall's most frequent co-authors are Kenny H. Chan, MD and Shelby C. Leuin, MD.

CMS Open Payments shows 14 general payments to Dr. Frydendall from 3 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $173.

Dr. Frydendall graduated from University of Colorado School of Medicine, Denver in 2014.